Second, by stratifying gliomas according to IDH status—a critical molecular determinant of tumor biology—we reveal that MGMT promoter methylation significantly correlates with elevated rADCmin exclusively in IDH-wildtype gliomas (AUC = 0.78, sensitivity = 80.0% at cutoff 1.10). Here, IDH2 is linked to central nervous system cancer.